{"id":"placebo-xeomin","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Headache"},{"rate":"1-5","effect":"Injection site pain"},{"rate":"1-3","effect":"Eyelid ptosis"},{"rate":"1-5","effect":"Muscle weakness"},{"rate":"2-8","effect":"Neck pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Xeomin (incobotulinumtoxinA) is a purified botulinum toxin serotype A that cleaves SNARE proteins required for acetylcholine vesicle release. This results in temporary denervation and muscle relaxation at the injection site. The effect is reversible as new neuromuscular junctions form over several months.","oneSentence":"Xeomin is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:02.242Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cervical dystonia"},{"name":"Blepharospasm"},{"name":"Hemifacial spasm"},{"name":"Glabellar lines (aesthetic indication)"},{"name":"Crow's feet (aesthetic indication)"}]},"trialDetails":[{"nctId":"NCT07486830","phase":"PHASE2","title":"IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction","status":"RECRUITING","sponsor":"Center for Vulvovaginal Disorders","startDate":"2026-02-27","conditions":"Provoked Vestibulodynia","enrollment":54},{"nctId":"NCT07018700","phase":"PHASE3","title":"A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine","status":"RECRUITING","sponsor":"Merz Therapeutics GmbH","startDate":"2025-08-21","conditions":"Episodic Migraine","enrollment":990},{"nctId":"NCT07018713","phase":"PHASE3","title":"A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine","status":"RECRUITING","sponsor":"Merz Therapeutics GmbH","startDate":"2025-08-21","conditions":"Chronic Migraine","enrollment":780},{"nctId":"NCT03992404","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2019-09-16","conditions":"Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury","enrollment":603},{"nctId":"NCT03977493","phase":"PHASE3","title":"IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia","status":"RECRUITING","sponsor":"Alain Kaelin","startDate":"2018-02-21","conditions":"Focal Hand Dystonia","enrollment":48},{"nctId":"NCT07426640","phase":"NA","title":"Dual-Site Botulinum Toxin Type A Injection for Lifelong Premature Ejaculation","status":"COMPLETED","sponsor":"Al Mouwasat Hospital","startDate":"2021-11-01","conditions":"Premature (Early) Ejaculation","enrollment":150},{"nctId":"NCT07210463","phase":"PHASE3","title":"A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)","status":"RECRUITING","sponsor":"Merz Aesthetics GmbH","startDate":"2025-10-01","conditions":"Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs","enrollment":300},{"nctId":"NCT06995287","phase":"PHASE3","title":"Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Severe Primary Dysmenorrhea","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-02-09","conditions":"Primary Dysmenorrhea, Chronic Pelvic Pain","enrollment":222},{"nctId":"NCT07122193","phase":"PHASE3","title":"A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States","status":"RECRUITING","sponsor":"Merz North America, Inc.","startDate":"2025-08-27","conditions":"Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs","enrollment":300},{"nctId":"NCT06604832","phase":"PHASE1","title":"Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture","status":"COMPLETED","sponsor":"Kalpna Kay Durairaj, MD, FACS","startDate":"2024-09-03","conditions":"Skin Aging, Skin Wrinkling","enrollment":20},{"nctId":"NCT06091020","phase":"PHASE2","title":"A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury","status":"COMPLETED","sponsor":"Merz Therapeutics GmbH","startDate":"2023-11-22","conditions":"Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury","enrollment":123},{"nctId":"NCT07070817","phase":"NA","title":"A Clinical Study of Ultrasound-guided Botulinum Toxin A Into Salivary Gland for Sialorrhea After True Bulbar Palsy","status":"ENROLLING_BY_INVITATION","sponsor":"houyajing","startDate":"2024-06-01","conditions":"Sialorrhea True Bulbar Palsy Medullary Injury","enrollment":70},{"nctId":"NCT05327972","phase":"PHASE2","title":"DEgenerative ROtator Cuff Disease and Botulinum TOXin","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-01-20","conditions":"Degenerative Rotator Cuff Disease","enrollment":60},{"nctId":"NCT03985982","phase":"PHASE3","title":"Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)","status":"COMPLETED","sponsor":"Croma-Pharma GmbH","startDate":"2019-04-29","conditions":"Glabellar Frown Lines","enrollment":410},{"nctId":"NCT04075981","phase":"PHASE3","title":"Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-09-30","conditions":"Cardiac Surgery","enrollment":220},{"nctId":"NCT02677805","phase":"PHASE3","title":"Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II","status":"COMPLETED","sponsor":"Croma-Pharma GmbH","startDate":"2016-03-30","conditions":"Glabellar Frown Lines","enrollment":251},{"nctId":"NCT02677298","phase":"PHASE3","title":"Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I","status":"COMPLETED","sponsor":"Croma-Pharma GmbH","startDate":"2016-03-02","conditions":"Glabellar Frown Lines","enrollment":784},{"nctId":"NCT06793683","phase":"EARLY_PHASE1","title":"Early BOTOX After Spinal Cord Injury","status":"ENROLLING_BY_INVITATION","sponsor":"University of Washington","startDate":"2024-07-27","conditions":"Spinal Cord Injuries","enrollment":10},{"nctId":"NCT06499324","phase":"PHASE3","title":"Surgery with Botulinum Toxin a for Incisional Hernia","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-01-17","conditions":"Incisional Hernia","enrollment":260},{"nctId":"NCT05196308","phase":"PHASE2","title":"Efficacy of Intracavernosal as add-on Therapy to Sildenafil 100 mg on Demand Compared to Sildenafil 100 mg on Demand for the Treatment of Erectile Dysfunction (ED) Not Sufficiently Responsive to Standard Therapy With Phosphodiesterase Type 5 Inhibitors","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-03-18","conditions":"Erectile Dysfunction","enrollment":226},{"nctId":"NCT05146999","phase":"PHASE3","title":"Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2022-05-09","conditions":"Glabellar Frown Lines","enrollment":132},{"nctId":"NCT05773053","phase":"PHASE2","title":"A Study of NT 201 Doses in the Treatment of Platysma Prominence","status":"COMPLETED","sponsor":"Merz Aesthetics GmbH","startDate":"2023-03-22","conditions":"Platysma Prominence","enrollment":73},{"nctId":"NCT05784363","phase":"PHASE1","title":"A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2022-10-27","conditions":"Enlarged Pores, Sebum Production","enrollment":31},{"nctId":"NCT04622254","phase":"PHASE3","title":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2020-11-12","conditions":"Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)","enrollment":368},{"nctId":"NCT04594213","phase":"PHASE3","title":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2020-09-23","conditions":"Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)","enrollment":362},{"nctId":"NCT04766723","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2021-02-24","conditions":"Essential Tremor of the Upper Limb","enrollment":78},{"nctId":"NCT06345677","phase":"NA","title":"Clinical Trial for the Assessment of Safety, Usability and Efficacy of the Vixe Combination for OAB in Female Subjects","status":"COMPLETED","sponsor":"Vensica Therapeutics Ltd.","startDate":"2023-06-09","conditions":"Overactive Bladder","enrollment":48},{"nctId":"NCT06331533","phase":"PHASE4","title":"Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea","status":"COMPLETED","sponsor":"Istanbul Training and Research Hospital","startDate":"2022-11-01","conditions":"Erythematotelangiectatic Rosacea","enrollment":30},{"nctId":"NCT06250543","phase":"PHASE4","title":"Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder","status":"COMPLETED","sponsor":"Niko Kavcic","startDate":"2018-08-14","conditions":"Overactive Bladder","enrollment":64},{"nctId":"NCT03380559","phase":"PHASE3","title":"A Phase III Study to Evaluate Efficacy of Botulinum Toxin for Treating Epicondylitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-04-19","conditions":"Epicondylitis","enrollment":33},{"nctId":"NCT04247074","phase":"PHASE3","title":"Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2020-02-10","conditions":"Glabellar Frown Lines (GL), Lateral Canthal Lines (LCL)","enrollment":413},{"nctId":"NCT02088632","phase":"PHASE2","title":"Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia","status":"TERMINATED","sponsor":"Thomas Jefferson University","startDate":"2014-03-14","conditions":"Trigeminal Neuralgia","enrollment":6},{"nctId":"NCT04249583","phase":"PHASE3","title":"Treatment of Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2020-02-10","conditions":"Glabellar Frown Lines","enrollment":300},{"nctId":"NCT04249687","phase":"PHASE3","title":"Treatment of Moderate to Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2020-02-10","conditions":"Lateral Canthal Lines","enrollment":303},{"nctId":"NCT02107261","phase":"PHASE2","title":"Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2014-03","conditions":"Dystonia","enrollment":21},{"nctId":"NCT05604729","phase":"NA","title":"The Effect on Envelope of Motion in Asymptomatic Bruxers","status":"UNKNOWN","sponsor":"Region Västerbotten","startDate":"2023-09-01","conditions":"Tooth Wear, Bruxism","enrollment":60},{"nctId":"NCT05605886","phase":"EARLY_PHASE1","title":"Botulinum Toxin A in Patients With Myofascial Pain Syndrome With and Without Zinc Supplementation","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-05-20","conditions":"Myofacial Pain Syndrome, Botulinum Toxin","enrollment":24},{"nctId":"NCT04810429","phase":"PHASE4","title":"Comparison of Temporomandibular Joint Arthroscopy With Botulinum Toxin Injection Versus Placebo","status":"COMPLETED","sponsor":"Instituto Portugues da Face","startDate":"2021-01-01","conditions":"Temporomandibular Joint Disorders","enrollment":15},{"nctId":"NCT05411900","phase":"PHASE2","title":"BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome","status":"UNKNOWN","sponsor":"Francesco Bono","startDate":"2022-05-25","conditions":"Carpal Tunnel Syndrome, Neurogenic Inflammation, Pain","enrollment":164},{"nctId":"NCT05275647","phase":"PHASE2","title":"Efficacy and Safety of Low Energy Shock Wave Plus BotulinumToxin A in Treating Patients With Interstitial Cystitis","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2021-05-18","conditions":"Interstitial Cystitis","enrollment":75},{"nctId":"NCT02270736","phase":"PHASE3","title":"Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2015-02-09","conditions":"Chronic Troublesome Sialorrhea, Cerebral Palsy, Stroke","enrollment":256},{"nctId":"NCT02207946","phase":"PHASE2","title":"Botulinum Toxin A to Treat Arm Tremor","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2014-12-05","conditions":"Essential Tremor of the Upper Limbs","enrollment":30},{"nctId":"NCT01614743","phase":"PHASE2","title":"A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea","status":"COMPLETED","sponsor":"DeNova Research","startDate":"2012-06","conditions":"Rosacea","enrollment":9},{"nctId":"NCT02091739","phase":"PHASE3","title":"Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2014-04","conditions":"Chronic Troublesome Sialorrhea, Parkinson's Disease, Post-stroke","enrollment":184},{"nctId":"NCT01896895","phase":"PHASE3","title":"Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2013-11","conditions":"Bilateral Blepharospasm (BEB)","enrollment":61},{"nctId":"NCT03181802","phase":"PHASE3","title":"Are Paraspinous Intramuscular Injections of Botulinum Toxin A (BoNT-A) Efficient in the Treatment of Chronic Low-back Pain (LBP)?","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2003-11-18","conditions":"Chronic Low-back Pain","enrollment":19},{"nctId":"NCT03119948","phase":"PHASE2","title":"Partial Blocks of Rectus Femoris and Soleus With Botulinum Toxin Type A (Xeomin®) to Improve Gait in Hemiparesis","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-12","conditions":"Hemiparesis After Stroke, Traumatic Brain Injury","enrollment":66},{"nctId":"NCT01968902","phase":"PHASE4","title":"Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Multiple Sclerosis Center of Northeastern New York","startDate":"2013-11","conditions":"Muscle Spasticity, Multiple Sclerosis","enrollment":27},{"nctId":"NCT01653132","phase":"PHASE2","title":"Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2012-03","conditions":"Sialorrhea","enrollment":10},{"nctId":"NCT02247557","phase":"PHASE2","title":"Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis","status":"COMPLETED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2014-09","conditions":"Interstitial Cystitis","enrollment":90},{"nctId":"NCT01733290","phase":"PHASE2","title":"Botulinum Toxin Urethral Sphincter Injection for Dysfunctional Voiding","status":"COMPLETED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2012-10","conditions":"Dysfunctional Voiding","enrollment":70},{"nctId":"NCT01969773","phase":"PHASE2","title":"Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment","status":"COMPLETED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2012-12","conditions":"Interstitial Cystitis","enrollment":60},{"nctId":"NCT01565395","phase":"PHASE2","title":"Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)","status":"WITHDRAWN","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2012-03","conditions":"Parkinson Disease, Amyotrophic Lateral Sclerosis","enrollment":""},{"nctId":"NCT01678001","phase":"PHASE4","title":"Treatment of Plantar Fasciitis With Xeomin","status":"COMPLETED","sponsor":"Rothman Institute Orthopaedics","startDate":"2012-08","conditions":"Plantar Fascitis","enrollment":50},{"nctId":"NCT01392300","phase":"PHASE3","title":"Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2011-09","conditions":"Post-stroke Spasticity of the Upper Limb","enrollment":317},{"nctId":"NCT01464307","phase":"PHASE3","title":"Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2011-12","conditions":"Post-stroke Spasticity of the Lower Limb","enrollment":290},{"nctId":"NCT01931878","phase":"PHASE2","title":"Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.","status":"COMPLETED","sponsor":"Yale University","startDate":"2012-09","conditions":"Restless Leg Syndrome","enrollment":24},{"nctId":"NCT02419313","phase":"PHASE2","title":"Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach","status":"COMPLETED","sponsor":"Yale University","startDate":"2012-08","conditions":"Parkinson, Tremor","enrollment":33},{"nctId":"NCT00773591","phase":"PHASE2","title":"Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing Disorders","status":"WITHDRAWN","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2010-03","conditions":"Sleep-Disordered Breathing","enrollment":""},{"nctId":"NCT02212119","phase":"PHASE2","title":"Safety and Effectiveness of Botulinum Toxin in Elderly Patients With Dementia and Muscle Stiffness","status":"COMPLETED","sponsor":"Assistive Technology Clinic, Canada","startDate":"2010-12","conditions":"Dementia, Paratonia","enrollment":10},{"nctId":"NCT01842529","phase":"PHASE2","title":"Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery","status":"COMPLETED","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2012-09","conditions":"Paroxysmal Atrial Fibrillation, Indications for CABG","enrollment":60},{"nctId":"NCT00407030","phase":"PHASE3","title":"IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2006-07","conditions":"Cervical Dystonia","enrollment":233},{"nctId":"NCT01515371","phase":"PHASE2","title":"Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring","status":"TERMINATED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2012-01","conditions":"Habitual Snoring","enrollment":8},{"nctId":"NCT00406367","phase":"PHASE3","title":"IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2006-10","conditions":"Blepharospasm","enrollment":109},{"nctId":"NCT00770029","phase":"PHASE3","title":"IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2008-10","conditions":"Moderate to Severe Glabellar Frown Lines","enrollment":276},{"nctId":"NCT01098019","phase":"PHASE3","title":"Treatment of Notalgia Paresthetica With Xeomin","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2010-04","conditions":"Notalgia Paresthetica","enrollment":20},{"nctId":"NCT00541723","phase":"PHASE3","title":"Efficacy and Safety of NT 201 in the Treatment of Lateral Periorbital Wrinkles","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2007-09","conditions":"Lateral Periorbital Wrinkles","enrollment":111},{"nctId":"NCT00430963","phase":"PHASE3","title":"IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2006-10","conditions":"Glabellar Frown Lines","enrollment":256},{"nctId":"NCT00770211","phase":"PHASE3","title":"IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2008-10","conditions":"Moderate to Severe Glabellar Frown Lines","enrollment":271},{"nctId":"NCT00430586","phase":"PHASE2","title":"Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2006-11","conditions":"Glabellar Frown Lines","enrollment":191},{"nctId":"NCT01405482","phase":"PHASE1","title":"Botulinum Toxin Injections for Thoracic Outlet Syndrome","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2011-08","conditions":"Thoracic Outlet Syndrome","enrollment":60},{"nctId":"NCT00909883","phase":"PHASE3","title":"Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2009-09","conditions":"Parkinson's Disease, Foot Dystonia","enrollment":45},{"nctId":"NCT00432666","phase":"PHASE3","title":"IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2006-06","conditions":"Post-stroke Upper Limb Spasticity","enrollment":148}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sodium Chloride","Saline"],"phase":"phase_3","status":"active","brandName":"Placebo / Xeomin","genericName":"Placebo / Xeomin","companyName":"Innovaderm Research Inc.","companyId":"innovaderm-research-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Xeomin is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}